Vaxcyte (PCVX) traded higher as attention returned to its lead pneumococcal vaccine candidate, VAX-31, following the company’s March 2026 research publication and its refreshed milestone timeline for the Phase 3 OPUS program. The updated pipeline guidance (dated March 23, 2026) keeps the focus on upcoming clinical readouts rather than near-term revenue, which is typical for a clinical-stage vaccine developer.

Vaxcyte’s pipeline materials point investors to a March 2026 publication in The Lancet Infectious Diseases for VAX-31 Phase 1/2 results, alongside a clear set of expected Phase 3 readouts. The company’s stated timeline calls for OPUS-1 Phase 3 topline safety, tolerability and immunogenicity data in the fourth quarter of 2026, with OPUS-2 and OPUS-3 Phase 3 results expected in the first half of 2027; OPUS-2 evaluates co-administration with a seasonal influenza vaccine, and OPUS-3 evaluates VAX-31 in previously vaccinated adults.

While PCVX can react sharply to any sign of additional dilution, investors have had relatively clear signposts on financing tools. In late February 2026, the company disclosed a new sales agreement allowing it to sell up to $500 million of common stock from time to time, replacing an older open-market sale agreement, which keeps optionality available as Phase 3 costs rise.

Near-term trading will likely track incremental OPUS execution updates and any new disclosures around enrollment progress, trial operations, or manufacturing readiness, with the next major valuation inflection centered on OPUS-1 topline data expected in Q4 2026. Any changes to the guidance dates, trial size, or financing cadence could quickly reshape sentiment given the company’s clinical-stage profile.